| __timestamp | AstraZeneca PLC | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 13324000000 | 2983000000 |
| Thursday, January 1, 2015 | 11451000000 | 3426000000 |
| Friday, January 1, 2016 | 9739000000 | 3398000000 |
| Sunday, January 1, 2017 | 10543000000 | 3878000000 |
| Monday, January 1, 2018 | 10362000000 | 4056000000 |
| Tuesday, January 1, 2019 | 11848000000 | 4381000000 |
| Wednesday, January 1, 2020 | 11693000000 | 5151000000 |
| Friday, January 1, 2021 | 15680000000 | 5246000000 |
| Saturday, January 1, 2022 | 18955000000 | 5673000000 |
| Sunday, January 1, 2023 | 18025000000 | 6090000000 |
In pursuit of knowledge
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, AstraZeneca PLC and Gilead Sciences, Inc. have shown distinct strategies in optimizing these costs. AstraZeneca's SG&A expenses have seen a significant increase, peaking at approximately 18.0 billion in 2022, a 35% rise from 2014. In contrast, Gilead Sciences maintained a more stable trajectory, with expenses growing from around 3.0 billion in 2014 to 6.1 billion in 2023, reflecting a 104% increase. This suggests AstraZeneca's aggressive investment in administrative functions, while Gilead's steadier approach may indicate a focus on cost efficiency. Understanding these trends provides valuable insights into each company's strategic priorities and operational efficiencies over the past decade.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and AstraZeneca PLC
Breaking Down SG&A Expenses: AbbVie Inc. vs AstraZeneca PLC
Key Insights on Gross Profit: AstraZeneca PLC vs Gilead Sciences, Inc.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Insmed Incorporated
AstraZeneca PLC and Grifols, S.A.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Alkermes plc
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited